149 related articles for article (PubMed ID: 30506895)
1. The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.
Graf SA; Heppt MV; Wessely A; Krebs S; Kammerbauer C; Hornig E; Strieder A; Blum H; Bosserhoff AK; Berking C
Pigment Cell Melanoma Res; 2019 May; 32(3):424-434. PubMed ID: 30506895
[TBL] [Abstract][Full Text] [Related]
2. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity.
Graf SA; Busch C; Bosserhoff AK; Besch R; Berking C
J Invest Dermatol; 2014 Aug; 134(8):2212-2220. PubMed ID: 24608986
[TBL] [Abstract][Full Text] [Related]
3. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
4. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
5. Functional in vivo characterization of sox10 enhancers in neural crest and melanoma development.
Cunningham RL; Kramer ET; DeGeorgia SK; Godoy PM; Zarov AP; Seneviratne S; Grigura V; Kaufman CK
Commun Biol; 2021 Jun; 4(1):695. PubMed ID: 34099848
[TBL] [Abstract][Full Text] [Related]
6. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
7. Stringent comparative sequence analysis reveals SOX10 as a putative inhibitor of glial cell differentiation.
Gopinath C; Law WD; Rodríguez-Molina JF; Prasad AB; Song L; Crawford GE; Mullikin JC; Svaren J; Antonellis A
BMC Genomics; 2016 Nov; 17(1):887. PubMed ID: 27821050
[TBL] [Abstract][Full Text] [Related]
8. Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7α modulates melanoma cell migration.
Lv XB; Wu W; Tang X; Wu Y; Zhu Y; Liu Y; Cui X; Chu J; Hu P; Li J; Guo Q; Cai Z; Wu J; Hu K; Ouyang N
Oncotarget; 2015 Nov; 6(34):36370-82. PubMed ID: 26461473
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.
Shakhova O; Cheng P; Mishra PJ; Zingg D; Schaefer SM; Debbache J; Häusel J; Matter C; Guo T; Davis S; Meltzer P; Mihic-Probst D; Moch H; Wegner M; Merlino G; Levesque MP; Dummer R; Santoro R; Cinelli P; Sommer L
PLoS Genet; 2015 Jan; 11(1):e1004877. PubMed ID: 25629959
[TBL] [Abstract][Full Text] [Related]
10. Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype.
Slutsky SG; Kamaraju AK; Levy AM; Chebath J; Revel M
J Biol Chem; 2003 Mar; 278(11):8960-8. PubMed ID: 12643284
[TBL] [Abstract][Full Text] [Related]
11. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
12. SOX5 is involved in balanced MITF regulation in human melanoma cells.
Kordaß T; Weber CE; Oswald M; Ast V; Bernhardt M; Novak D; Utikal J; Eichmüller SB; König R
BMC Med Genomics; 2016 Feb; 9():10. PubMed ID: 26927636
[TBL] [Abstract][Full Text] [Related]
13. The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor.
Coe EA; Tan JY; Shapiro M; Louphrasitthiphol P; Bassett AR; Marques AC; Goding CR; Vance KW
PLoS Genet; 2019 Dec; 15(12):e1008501. PubMed ID: 31881017
[TBL] [Abstract][Full Text] [Related]
14. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
15. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.
Williams EA; Ravindranathan A; Gupta R; Stevers NO; Suwala AK; Hong C; Kim S; Yuan JB; Wu J; Barreto J; Lucas CG; Chan E; Pekmezci M; LeBoit PE; Mully T; Perry A; Bollen A; Van Ziffle J; Devine WP; Reddy AT; Gupta N; Basnet KM; Macaulay RJB; Malafronte P; Lee H; Yong WH; Williams KJ; Juratli TA; Mata DA; Huang RSP; Hiemenz MC; Pavlick DC; Frampton GM; Janovitz T; Ross JS; Chang SM; Berger MS; Jacques L; Song JS; Costello JF; Solomon DA
Neuro Oncol; 2023 Dec; 25(12):2221-2236. PubMed ID: 37436963
[TBL] [Abstract][Full Text] [Related]
16. Glutamate-dependent transcriptional control in Bergmann glia: Sox10 as a repressor.
Cruz-Solis I; Zepeda RC; Ortiz S; Aguilera J; López-Bayghen E; Ortega A
J Neurochem; 2009 May; 109(3):899-910. PubMed ID: 19425178
[TBL] [Abstract][Full Text] [Related]
17. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.
Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L
Nat Cell Biol; 2012 Aug; 14(8):882-90. PubMed ID: 22772081
[TBL] [Abstract][Full Text] [Related]
18. SOX10 regulates expression of the SH3-domain kinase binding protein 1 (Sh3kbp1) locus in Schwann cells via an alternative promoter.
Hodonsky CJ; Kleinbrink EL; Charney KN; Prasad M; Bessling SL; Jones EA; Srinivasan R; Svaren J; McCallion AS; Antonellis A
Mol Cell Neurosci; 2012 Feb; 49(2):85-96. PubMed ID: 22037207
[TBL] [Abstract][Full Text] [Related]
19. SOX10 transactivates S100B to suppress Schwann cell proliferation and to promote myelination.
Fujiwara S; Hoshikawa S; Ueno T; Hirata M; Saito T; Ikeda T; Kawaguchi H; Nakamura K; Tanaka S; Ogata T
PLoS One; 2014; 9(12):e115400. PubMed ID: 25536222
[TBL] [Abstract][Full Text] [Related]
20. SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death.
Rosenbaum SR; Caksa S; Stefanski CD; Trachtenberg IV; Wilson HP; Wilski NA; Ott CA; Purwin TJ; Haj JI; Pomante D; Kotas D; Chervoneva I; Capparelli C; Aplin AE
Mol Cancer Res; 2024 Feb; 22(2):209-220. PubMed ID: 37847239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
